Skip to main content
. 2016 Mar 31;3(3):e223. doi: 10.1212/NXI.0000000000000223

Figure 2. Differential expression of POU2AF1 and Spi-B mRNA in PBMCs upon natalizumab treatment and PML.

Figure 2

Transcriptional expression of POU2AF1 (A) and Spi-B (B) were analyzed with real-time reverse transcription PCR in PBMCs from untreated patients, natalizumab-treated patients with relapsing-remitting multiple sclerosis (1–24 mo, >24 mo), and patients with natalizumab-associated PML. Relative expression levels (median with interquartile range) are depicted. ***p < 0.001, **p < 0.01, *p < 0.05. Nat = natalizumab; PBMC = peripheral blood mononuclear cell; PML = progressive multifocal leukoencephalopathy.